Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/19w27070

INVESTIGATING THE BIOCHEMICAL PATHWAYS INVOLVED IN GYNECOLOGICAL AGING: A STUDY OF HORMONAL FLUCTUATIONS, OXIDATIVE STRESS, AND THEIR IMPLICATIONS FOR REPRODUCTIVE HEALTH

Dr Tehmina Aziz[1*], Dr Beenish Haleem Riaz[2], Dr Ambreen Liaqat[3], Dr Fauzia Shaokat[4], Dr Nooria Hassan[5], Dr Mariam Zakia Chaudhari[6], Muhammad Shayyan Latif[7]

[1*]Consultant obe & gyn, Al-yamama hospital, Riyadh Second Health Cluster
[2]Demonstrator, Gujranwala Medical College
[3]Assistant Principal Medical Officer, Gujranwala Medical College
[4]Demonstrator, Department of Biochemistry, Gujranwala Medical College.
[5]Demonstrator, Department of Biochemistry, Gujranwala Medical College.
[6]Assistant Professor Ophthalmology, Amna Inayat Medical College
[7]Clinical Optometrist, Rehmat Tufail Trust Hospital, Canal View, Lahore

***Corresponding Author:** Dr Tehmina Aziz
[*]Consultant obe & gyn, Al-yamama hospital, Riyadh Second Health Cluster

Abstract

Objective: This study investigates the biochemical pathways involved in gynecological aging, focusing on the role of hormonal fluctuations and oxidative stress and their implications for reproductive health.

Methods: A cross-sectional observational study was conducted with 65 female participants aged 40–60 years. Hormonal levels (estrogen, progesterone, and FSH) and oxidative stress markers (MDA and TAC) were measured using blood samples. Patients were classified into early perimenopause, late perimenopause, and postmenopause groups. Statistical analyses, including correlation and regression, were used to evaluate relationships between hormones, oxidative stress, and aging.

Results: Estrogen and progesterone levels significantly decreased across the stages of reproductive aging, while FSH levels increased. Oxidative stress markers (MDA) rose, and antioxidant capacity (TAC) declined, especially in postmenopausal women. A strong negative correlation was found between estrogen and oxidative stress, while FSH positively correlated with oxidative damage.

Conclusion: It is concluded that hormonal fluctuations, particularly the decline in estrogen, combined with increased oxidative stress, accelerate gynecological aging and negatively impact reproductive health. Therapeutic approaches targeting oxidative stress and hormonal regulation may improve outcomes for aging women.

Keywords: Gynecological aging, hormonal fluctuations, oxidative stress, reproductive health, menopause.

Introduction

Gynecological aging is a multifaceted process that significantly affects a woman's reproductive health and overall well-being. This biological phenomenon is largely governed by hormonal changes,

oxidative stress, and other biochemical pathways that influence cellular function and tissue integrity [1]. As women age, particularly during perimenopause and menopause, there is a marked decline in reproductive hormones, especially estrogen and progesterone, which play pivotal roles in maintaining reproductive tissues, bone health, and cardiovascular function. These hormonal fluctuations not only contribute to the aging process but also expose the body to various physiological changes that can impact fertility, menstrual cycles, and other aspects of reproductive health [2]. One of the primary drivers of gynecological aging is the fluctuation of hormone levels over time. Estrogen, for instance, is essential for regulating the menstrual cycle, maintaining the thickness of the uterine lining, and ensuring the proper functioning of the ovaries [3] . During a woman's reproductive years, estrogen levels are relatively stable, promoting healthy reproductive function. However, as women approach menopause, estrogen production in the ovaries gradually decreases, leading to symptoms such as irregular menstruation, hot flashes, and vaginal atrophy [4]. Progesterone levels also decline, further affecting the balance of the reproductive system. These hormonal changes not only mark the end of fertility but also contribute to the onset of various age-related conditions, such as osteoporosis, cardiovascular disease, and increased risk of gynecological cancers. Oxidative stress is another critical factor in the aging process, including gynecological aging [5]. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize these harmful molecules with antioxidants. ROS are byproducts of normal cellular metabolism, but when produced in excess, they can cause significant damage to cells, proteins, lipids, and DNA [6]. This oxidative damage accelerates the aging process and plays a pivotal role in the degeneration of reproductive tissues. In the ovaries, for example, oxidative stress can lead to the depletion of ovarian follicles, reducing a woman's fertility and hastening the onset of menopause [7]. Furthermore, oxidative stress has been linked to complications such as polycystic ovary syndrome (PCOS), endometriosis, and ovarian aging, all of which can negatively affect a woman's reproductive potential and quality of life. The interplay between hormonal fluctuations and oxidative stress is particularly important in understanding the biochemical pathways involved in gynecological aging. Estrogen, for example, has antioxidant properties that protect cells from oxidative damage. As estrogen levels decline with age, the body becomes more vulnerable to oxidative stress, which in turn accelerates the aging of reproductive tissues [8]. The decrease in estrogen's protective effects exacerbates the impact of ROS, leading to an increased risk of gynecological conditions such as uterine fibroids, endometrial hyperplasia, and ovarian cysts. Moreover, oxidative stress can disrupt the hormonal balance itself, creating a vicious cycle in which hormonal imbalances promote oxidative damage, and oxidative stress, in turn, worsens hormonal dysregulation [9]. The implications of these biochemical changes for reproductive health are profound. As women age, they experience a natural decline in fertility, which is compounded by the effects of oxidative stress and hormonal fluctuations. The reduction in ovarian reserve, or the number of viable eggs in the ovaries, is a key factor in age-related infertility [10]. Oxidative stress can further diminish ovarian reserve by accelerating the depletion of ovarian follicles and causing DNA damage to the oocytes. This not only affects fertility but also increases the risk of miscarriage and other pregnancy complications in older women. Additionally, the hormonal changes associated with aging can lead to menstrual irregularities, making it difficult for women to predict their ovulation and fertility windows [11].

Objective

The main objective of the study is to find the biochemical pathways involved in gynecological aging and hormonal fluctuations, oxidative stress, and their implications for reproductive health.

Methodology

This study was designed to investigate the biochemical pathways involved in gynecological aging, with a focus on hormonal fluctuations, oxidative stress, and their implications for reproductive health. A total of 65 female patients were recruited for the study, all of whom were experiencing varying stages of reproductive aging, including perimenopause and menopause. The patients were selected

based on specific inclusion and exclusion criteria to ensure a homogenous study group and accurate data analysis.

Inclusion Criteria:
- Women aged 40 to 60 years
- Women experiencing regular, irregular, or absent menstrual cycles
- No history of hormone replacement therapy (HRT) within the past six months
- No chronic conditions such as diabetes or autoimmune diseases that could interfere with oxidative stress levels

Exclusion Criteria:
- Women under the age of 40 or over the age of 60
- Women currently using hormone therapy, or who had used it in the last six months
- Women with known endocrine disorders, such as thyroid disease
- Women with a history of cancer or gynecological surgeries, such as hysterectomy

Study Design:
The research was conducted as a cross-sectional observational study over a period of six months. Each patient underwent a comprehensive clinical evaluation, which included a detailed reproductive history and a gynecological examination. Blood samples were collected to measure hormone levels, specifically estrogen, progesterone, and follicle-stimulating hormone (FSH), which are key indicators of reproductive aging. Additionally, oxidative stress markers, such as malondialdehyde (MDA) and total antioxidant capacity (TAC), were assessed through serum analysis to determine the extent of oxidative damage in the body.

Hormonal Fluctuations Assessment:
Hormonal levels were measured using enzyme-linked immunosorbent assay (ELISA) techniques to obtain precise readings of estrogen, progesterone, and FSH. The collected hormone data were used to categorize patients into different stages of reproductive aging, such as early perimenopause, late perimenopause, and postmenopause. These classifications helped to explore the relationship between specific hormonal changes and oxidative stress across different aging stages.

Oxidative Stress Measurement:
Oxidative stress was assessed by measuring key biomarkers. Serum levels of MDA, a marker of lipid peroxidation and oxidative damage, were determined using a thiobarbituric acid reactive substances (TBARS) assay. TAC was also measured to evaluate the body's antioxidant defense system. The ratio of MDA to TAC was calculated to assess the overall oxidative stress burden on each patient, providing insights into how hormonal fluctuations exacerbate oxidative damage during the aging process.

Statistical Analysis:
All data collected from the 65 patients were entered into a secure database for statistical analysis. The hormonal and oxidative stress data were analyzed using descriptive statistics to summarize the findings. A significance level of $p < 0.05$ was used for all tests to determine statistically significant relationships.

Results
The demographic data of the study population show an average age of 52.3 years, with patients ranging from 40 to 60 years old. The mean BMI was 26.5, indicating that most participants fell within the overweight range. Smoking status revealed that the majority (65%) were non-smokers, while 12% were current smokers and 23% were former smokers. Regarding menstrual status, 28% of participants

reported having regular menstrual cycles, 42% experienced irregular cycles, and 30% had amenorrhea (no menstrual cycles), reflecting varying stages of reproductive aging.

Table 1: Demographic Characteristics of Patients (n = 65)

Characteristic	Value
Mean Age (years)	52.3 ± 5.8
Age Range (years)	40–60
BMI (kg/m²)	26.5 ± 4.3
Smoking Status	
- Current Smokers	8 (12%)
- Former Smokers	15 (23%)
- Non-Smokers	42 (65%)
Menstrual Status	
- Regular Cycles	18 (28%)
- Irregular Cycles	27 (42%)
- Amenorrhea (No Cycles)	20 (30%)
Parity (Number of Children)	2.1 ± 1.3

The hormonal fluctuations in the study demonstrate a clear decline in estrogen and progesterone levels as women progress from early perimenopause to postmenopause. Estrogen levels decreased from 150 pg/mL in early perimenopause to just 20 pg/mL in postmenopause, while progesterone dropped from 8 ng/mL to 0.5 ng/mL during the same transition. Concurrently, FSH levels significantly increased, from 20 mIU/mL in early perimenopause to 75 mIU/mL in postmenopause.

Table 2: Hormonal Fluctuations Across Different Stages of Reproductive Aging

Group	Estrogen (pg/mL)	Progesterone (ng/mL)	FSH (mIU/mL)
Early Perimenopause	150 (120–180)	8 (6–10)	20 (15–25)
Late Perimenopause	80 (60–100)	3 (2–4)	40 (35–50)
Postmenopause	20 (10–30)	0.5 (0–1)	75 (65–90)

Oxidative stress markers show a notable increase as women move through the stages of reproductive aging. MDA, a marker of oxidative damage, rose from 2.5 µmol/L in early perimenopause to 5.0 µmol/L in postmenopause. At the same time, total antioxidant capacity (TAC) decreased from 1.5 mmol/L to 0.8 mmol/L, reflecting a reduction in the body's ability to combat oxidative stress. The MDA/TAC ratio increased from 1.67 in early perimenopause to 6.25 in postmenopause, indicating a substantial rise in oxidative stress burden in postmenopausal women.

Table 3: Oxidative Stress Markers Across Different Stages of Reproductive Aging

Group	MDA (µmol/L)	TAC (mmol/L)	MDA/TAC Ratio
Early Perimenopause	2.5 (2.0–3.0)	1.5 (1.2–1.8)	1.67
Late Perimenopause	3.8 (3.5–4.0)	1.2 (1.0–1.4)	3.17
Postmenopause	5.0 (4.5–5.5)	0.8 (0.6–1.0)	6.25

The correlation analysis reveals strong relationships between hormone levels and oxidative stress markers. Estrogen and progesterone showed strong negative correlations with MDA, with Pearson's r values of -0.75 and -0.68, respectively ($p < 0.01$), indicating that oxidative stress increases as these hormone levels decrease. Conversely, FSH exhibited a strong positive correlation with MDA ($r = 0.72$, $p < 0.01$).

Table 4: Correlation Between Hormonal Levels and Oxidative Stress Markers

Correlation	Pearson's r	p-value
Estrogen vs. MDA	-0.75	< 0.01
Progesterone vs. MDA	-0.68	< 0.01
FSH vs. MDA	0.72	< 0.01

The regression analysis identifies significant predictors of oxidative stress, with age, estrogen, progesterone, and FSH contributing to variations in MDA levels. Age ($\beta = 0.45$, $p < 0.01$) and FSH ($\beta = 0.38$, $p < 0.01$) were positively associated with oxidative stress, while estrogen ($\beta = -0.52$, $p < 0.01$) and progesterone ($\beta = -0.30$, $p = 0.02$) were negatively associated.

Table 4: Regression Analysis of Predictors of Oxidative Stress (MDA Levels)

Independent Variable	β (Beta Coefficient)	p-value
Age	0.45	< 0.01
Estrogen	-0.52	< 0.01
Progesterone	-0.30	0.02
FSH	0.38	< 0.01

Discussion

The results of this study provide valuable insights into the biochemical pathways involved in gynecological aging, particularly the interaction between hormonal fluctuations and oxidative stress, and their implications for reproductive health. By analyzing data from 65 women across different stages of reproductive aging, this research highlights the key role that declining hormone levels and increasing oxidative stress play in the aging process, particularly about reproductive tissues [12]. As expected, the study confirms that estrogen and progesterone levels decline significantly as women transition from early perimenopause to postmenopause. The findings align with previous research, which demonstrates that estrogen plays a vital role in maintaining reproductive function, protecting tissues from oxidative damage, and supporting overall health [13]. The sharp decline in estrogen levels observed in postmenopausal women is consistent with the onset of menopausal symptoms such as hot flashes, vaginal dryness, and decreased bone density, all of which are linked to reproductive aging. The elevation of FSH in postmenopausal women further validates this hormonal shift, as high FSH levels are a well-known marker of ovarian failure and menopause [14]. The correlation analysis suggests a strong inverse relationship between estrogen levels and oxidative stress (MDA), emphasizing estrogen's protective role against oxidative damage. These findings support the hypothesis that as hormone levels decline, the body becomes more vulnerable to oxidative stress, which exacerbates the aging of reproductive tissues [15]. The increase in oxidative stress across the stages of reproductive aging, as evidenced by rising MDA levels and declining TAC levels, provides critical insight into the cellular damage occurring during this process. This study shows that oxidative stress markers are significantly elevated in postmenopausal women compared to those in early or late perimenopause [16]. These results are consistent with prior studies indicating that oxidative stress accelerates ovarian aging, depletes ovarian follicles, and contributes to the decline in reproductive health. The strong positive correlation between FSH and oxidative stress suggests that higher FSH levels, commonly seen in postmenopausal women, may be linked to an increased oxidative burden. This correlation reinforces the idea that hormonal changes not only drive the reproductive aging process but also contribute to cellular damage through oxidative mechanisms [17]. The regression analysis further supports these findings, showing that age, estrogen, and FSH are significant predictors of oxidative stress, with estrogen serving as a protective factor and FSH as a contributor to oxidative damage. The results of this study have important implications for understanding the mechanisms of gynecological aging and its impact on women’s reproductive health [18]. The increased oxidative stress observed in postmenopausal women suggests that oxidative damage may play a role in the development of age-related reproductive disorders, such as ovarian aging, polycystic ovary syndrome (PCOS), and endometriosis [19]. These conditions, often characterized by impaired fertility and reproductive function, may be exacerbated by the oxidative damage that occurs during the aging process. The findings of this study suggest that targeting oxidative stress and hormone imbalances could be key strategies in addressing gynecological aging and its associated conditions. Hormone replacement therapy (HRT), while effective in alleviating some menopausal symptoms, carries potential risks and must be carefully managed. This study suggests that antioxidant

supplementation may be a complementary approach to reducing oxidative damage, especially in postmenopausal women who are at increased risk of oxidative stress-related tissue damage [20,21]. While this study provides valuable insights, there are some limitations to consider. First, the sample size of 65 participants is relatively small, which may limit the generalizability of the findings. Future studies with larger and more diverse populations would be beneficial to confirm these results. Additionally, this study focused on a cross-sectional design, which provides a snapshot of the relationship between hormonal fluctuations and oxidative stress at a single point in time. Longitudinal studies that track patients over time would provide a clearer understanding of how these biochemical pathways evolve and contribute to reproductive aging.

Conclusion

It is concluded that hormonal fluctuations, particularly the decline in estrogen and progesterone, along with increased oxidative stress, play a critical role in gynecological aging. The rise in oxidative stress markers, such as MDA, and the reduction in antioxidant capacity significantly contribute to reproductive tissue damage as women transition through menopause. Addressing oxidative stress and hormonal imbalances could be key in mitigating age-related reproductive health issues. Future therapeutic strategies may benefit from incorporating both hormone regulation and antioxidant treatments to improve reproductive health in aging women.

References

1. Fan, C.G., Tang, F.W., Zhang, Q.J., Lu, S.H., Liu, H.Y., Zhao, Z.M., Liu, B., Han, Z.B. and Han, Z.C., 2005. Characterization and neural differentiation of fetal lung mesenchymal stem cells. *Cell Transplantation*, 14, pp.311–321. doi:10.3727/000000005783983070.
2. McGuckin, C.P., Forraz, N., Baradez, M.O., Navran, S., Zhao, J., Urban, R., Tilton, R. and Denner, L., 2005. Production of stem cells with embryonic characteristics from human umbilical cord blood. *Cell Proliferation*, 38, pp.245–255. doi:10.1111/j.1365-2184.2005.00346.x.
3. Alviano, F., Fossati, V., Marchionni, C., Arpinati, M., Bonsi, L., Franchina, M., Lanzoni, G., Cantoni, S., Cavallini, C., Bianchi, F., et al., 2007. Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. *BMC Developmental Biology*, 7(11). doi:10.1186/1471-213X-7-11.
4. Mohamed-Ahmed, S., Fristad, I., Lie, S.A., Suliman, S., Mustafa, K., Vindenes, H. and Idris, S.B., 2018. Adipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison. *Stem Cell Research & Therapy*, 9(168). doi:10.1186/s13287-018-0914-1.
5. Xu, L., Liu, Y., Sun, Y., Wang, B., Xiong, Y., Lin, W., Wei, Q., Wang, H., He, W. and Wang, B., 2017. Tissue source determines the differentiation potentials of mesenchymal stem cells: A comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. *Stem Cell Research & Therapy*, 8(275). doi:10.1186/s13287-017-0716-x.
6. Chu, D.T., Nguyen Thi Phuong, T., Tien, N.L.B., Tran, D.K., Minh, L.B., Thanh, V.V., Gia Anh, P., Pham, V.H. and Thi Nga, V., 2019. Adipose tissue stem cells for therapy: An update on the progress of isolation, culture, storage, and clinical application. *Journal of Clinical Medicine*, 8(917). doi:10.3390/jcm8070917.
7. Si, Z., Wang, X., Sun, C., Kang, Y., Xu, J., Wang, X. and Hui, Y., 2019. Adipose-derived stem cells: Sources, potency, and implications for regenerative therapies. *Biomedicine & Pharmacotherapy*, 114, 108765. doi:10.1016/j.biopha.2019.108765.
8. Kim, W.S., Park, B.S. and Sung, J.H., 2009. The wound-healing and antioxidant effects of adipose-derived stem cells. *Expert Opinion on Biological Therapy*, 9(879–887). doi:10.1517/14712590903039684.
9. Kim, W.S., Park, B.S., Kim, H.K., Park, J.S., Kim, K.J., Choi, J.S., Chung, S.J., Kim, D.D. and Sung, J.H., 2008. Evidence supporting antioxidant action of adipose-derived stem cells: Protection of human dermal fibroblasts from oxidative stress. *Journal of Dermatological Science*, 49(133–142). doi:10.1016/j.jdermsci.2007.08.004.

10. Shih, Y.C., Lee, P.Y., Cheng, H., Tsai, C.H., Ma, H. and Tarng, D.C., 2013. Adipose-derived stem cells exhibit antioxidative and antiapoptotic properties to rescue ischemic acute kidney injury in rats. *Plastic and Reconstructive Surgery*, 132(940e–951e). doi:10.1097/PRS.0b013e3182a806ce.
11. Kim, Y., Jo, S.H., Kim, W.H. and Kweon, O.K., 2015. Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury. *Stem Cell Research & Therapy*, 6(229). doi:10.1186/s13287-015-0236-5.
12. Toda, A., Okabe, M., Yoshida, T. and Nikaido, T., 2007. The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. *Journal of Pharmacological Sciences*, 105(215–228). doi:10.1254/jphs.CR0070034.
13. Kim, E.Y., Lee, K.B. and Kim, M.K., 2014. The potential of mesenchymal stem cells derived from amniotic membrane and amniotic fluid for neuronal regenerative therapy. *BMB Reports*, 47(135–140). doi:10.5483/BMBRep.2014.47.3.289.
14. Tamagawa, T., Oi, S., Ishiwata, I., Ishikawa, H. and Nakamura, Y., 2007. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro. *Human Cell*, 20(77–84). doi:10.1111/j.1749-0774.2007.00032.x.
15. Valle-Prieto, A. and Conget, P.A., 2010. Human mesenchymal stem cells efficiently manage oxidative stress. *Stem Cells and Development*, 19(1885–1893). doi:10.1089/scd.2010.0093.
16. de Godoy, M.A., Saraiva, L.M., de Carvalho, L.R.P., Vasconcelos-Dos-Santos, A., Beiral, H.J.V., Ramos, A.B., Silva, L.R.P., Leal, R.B., Monteiro, V.H.S., Braga, C.V., et al., 2018. Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-beta oligomers. *Journal of Biological Chemistry*, 293(1957–1975). doi:10.1074/jbc.M117.807180.
17. Liu, H., McTaggart, S.J., Johnson, D.W. and Gobe, G.C., 2012. Anti-oxidant pathways are stimulated by mesenchymal stromal cells in renal repair after ischemic injury. *Cytotherapy*, 14(162–172). doi:10.3109/14653249.2011.613927.
18. Guillen, M.I., Platas, J., Perez Del Caz, M.D., Mirabet, V. and Alcaraz, M.J., 2018. Paracrine anti-inflammatory effects of adipose tissue-derived mesenchymal stem cells in human monocytes. *Frontiers in Physiology*, 9(661). doi:10.3389/fphys.2018.00661.
19. Laporte, C., Tubbs, E., Cristante, J., Gauchez, A.S., Pesenti, S., Lamarche, F., Cottet-Rousselle, C., Garrel, C., Moisan, A. and Moulis, J.M., 2019. Human mesenchymal stem cells improve rat islet functionality under cytokine stress with combined upregulation of heme oxygenase-1 and ferritin. *Stem Cell Research & Therapy*, 10(85). doi:10.1186/s13287-019-1190-4.
20. Stavely, R. and Nurgali, K., 2020. The emerging antioxidant paradigm of mesenchymal stem cell therapy. *Stem Cells Translational Medicine*, 9(985–1006). doi:10.1002/sctm.19-0446.
21. Liu, Q., Song, S., Song, L., Bi, Y., Zhu, K., Qiao, X., Wang, H., Gao, C., Cai, H. and Ji, G., 2022. Mesenchymal stem cells alleviate aging in vitro and in vivo. *Annals of Translational Medicine*, 10(1092). doi:10.21037/atm-22-1206.